University of California San Francisco

Michael J. Campbell, PhD

Michael Campbell headshot
Michael J. Campbell, PhD

Professor of Surgery
Division of Surgical Oncology

Address

2340 Sutter Street, #N321
San Francisco, CA 94115
United States

Email: [email protected]

Biography

Michael Campbell, Ph.D. received his doctoral degree in Cancer Biology from Stanford University where he remained as a postdoctoral fellow in Oncology. Dr. Campbell was appointed Assistant Professor of Surgery at Stanford University in 1992. He joined the UCSF faculty as Assistant Professor of Surgery in 1997.

Dr. Campbell's areas of interest in research include breast neoplasms, cancer vaccines, immunotherapy, immunologic adjuvants, immunologic and biological factors, gene therapy, immunology, and breast cancer.

Education

Education
  • 1978-82, University of Puget Sound, B.S., Biology
  • 1978-82, University of Puget Sound, B.S., Mathematics
  • 1983-87, Stanford University, Ph.D., Cancer Biology

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 62
  1. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
    Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, I-SPY2 Investigators, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L| | PubMed
  2. Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
    Ramalingam K, Woody R, Glencer A, Schwartz CJ, Mori H, Wong J, Hirst G, Rosenbluth J, Onishi N, Gibbs J, Hylton N, Borowsky AD, Campbell M, Esserman LJ| | PubMed
  3. Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
    Rugo HS, Campbell M, Yau C, Jo Chien A, Wallace AM, Isaacs C, Boughey JC, Han HS, Buxton M, Clennell JL, Asare SM, Steeg K, Wilson A, Singhrao R, Matthews JB, Perlmutter J, Fraser Symmans W, Hylton NM, DeMichele AM, Yee D, Van't Veer LJ, Berry DA, Esserman LJ| | PubMed
  4. Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
    Campbell MJ, Wolf DM, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher IR, Zhu Z, Bolen J, Vandenberg S, Hoyt C, Mori H, Borowsky A, Sit L, Perlmutter J, Asare SM, I-SPY2 Investigators, Nanda R, Liu MC, Yee D, DeMichele AM, Hylton NM, Pusztai L, Berry DA, Hirst GL, Petricoin EF, Veer LV, Esserman L| | PubMed
  5. Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women.
    McCune E, Sharma A, Johnson B, O'Meara T, Theiner S, Campos M, Heditsian D, Brain S, Gilbert JA, Esserman L, Campbell MJ| | PubMed
  6. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, Brabham C, Yau C, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky A, Hylton N, Esserman LJ, Basu A| | PubMed
  7. Tumor microenvironmental determinants of high-risk DCIS progression.
    Borowsky A, Glencer A, Ramalingam K, Schindler N, Mori H, Ghule P, Lee K, Nachmanson D, Officer A, Harismendy O, Stein J, Stein G, Evans M, Weaver D, Yau C, Hirst G, Campbell M, Esserman L| | PubMed
  8. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
    Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF| | PubMed
  9. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
    Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edmiston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele AM, van 't Veer LJ, Esserman LJ, Olopade OI| | PubMed
  10. B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
    Steenbruggen TG, Wolf DM, Campbell MJ, Sanders J, Cornelissen S, Thijssen B, Salgado RA, Yau C, O-Grady N, Basu A, Bhaskaran R, Mittempergher L, Hirst GL, Coppe JP, Kok M, Sonke GS, van 't Veer LJ, Horlings HM| | PubMed
  11. Adrenal Neoplasms: Lessons from Adrenal Multidisciplinary Tumor Boards.
    Chung R, Garratt J, Remer EM, Navin P, Blake MA, Taffel MT, Hackett CE, Sharbidre KG, Tu W, Low G, Bara M, Carney BW, Corwin MT, Campbell MJ, Lee JT, Lee CY, Dueber JC, Shehata MA, Caoili EM, Schieda N, Elsayes KM| | PubMed
  12. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ| | PubMed
  13. Limited disease progression in endocrine surgery patients with treatment delays due to COVID-19.
    Collins RA, DiGennaro C, Beninato T, Gartland RM, Chaves N, Broekhuis JM, Reddy L, Lee J, Deimiller A, Alterio MM, Campbell MJ, Lee YJ, Khilnani TK, Stewart LA, O'Brien MA, Alvarado MVY, Zheng F, McAneny D, Liou R, McManus C, Dream SY, Wang TS, Yen TW, Alhefdhi A, Finnerty BM, Fahey TJ, Graves CE, Laird AM, Nehs MA, Drake FT, Lee JA, McHenry CR, James BC, Pasieka JL, Kuo JH, Lubitz CC| | PubMed
  14. Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
    Glencer AC, Wong JM, Hylton NM, Krings G, McCune E, Rothschild HT, Loveday TA, Alvarado MD, Esserman LJ, Campbell MJ| | PubMed
  15. Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence.
    Mori H, Bolen J, Schuetter L, Massion P, Hoyt CC, VandenBerg S, Esserman L, Borowsky AD, Campbell MJ| | PubMed
  16. Germline genetic contribution to the immune landscape of cancer.
    Sayaman RW, Saad M, Thorsson V, Hu D, Hendrickx W, Roelands J, Porta-Pardo E, Mokrab Y, Farshidfar F, Kirchhoff T, Sweis RF, Bathe OF, Heimann C, Campbell MJ, Stretch C, Huntsman S, Graff RE, Syed N, Radvanyi L, Shelley S, Wolf D, Marincola FM, Ceccarelli M, Galon J, Ziv E, Bedognetti D| | PubMed
  17. Adrenal Tumors Found During Staging and Surveillance for Colorectal Cancer: Benign Incidentalomas or Metastatic Disease?
    Yanagisawa M, Malik DG, Loehfelm TW, Fananapazir G, Corwin MT, Campbell MJ| | PubMed
  18. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Amara D, Wolf DM, van 't Veer L, Esserman L, Campbell M, Yau C| | PubMed
  19. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
    Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L| | PubMed
  20. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
    Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ| | PubMed
  21. Biology of breast cancer in Nigerian women: a pilot study.
    Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, Tandon V, Mukhtar R, Greninger A, Risi JD, Esserman LJ| | PubMed
  22. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
    Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ| | PubMed
  23. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.
    Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ| | PubMed
  24. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.
    Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ| | PubMed
  25. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome.
    Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ| | PubMed
  26. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.
    Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ| | PubMed
  27. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID| | PubMed
  28. Breast cancer growth prevention by statins.
    Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC| | PubMed
  29. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
    Jabrane-Ferrat N, Campbell MJ, Esserman LJ, Peterlin BM| | PubMed
  30. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes.
    Kumar AS, Campbell M, Benz CC, Esserman LJ| | PubMed
  31. Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.
    Gable KL, Maddux BA, Penaranda C, Zavodovskaya M, Campbell MJ, Lobo M, Robinson L, Schow S, Kerner JA, Goldfine ID, Youngren JF| | PubMed
  32. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
    Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J, Goldfine ID| | PubMed
  33. In vitro anticancer activity of twelve Chinese medicinal herbs.
    Shoemaker M, Hamilton B, Dairkee SH, Cohen I, Campbell MJ| | PubMed
  34. Immune dysfunction and micrometastases in women with breast cancer.
    Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ| | PubMed
  35. Tid1, the human homologue of a Drosophila tumor suppressor, reduces the malignant activity of ErbB-2 in carcinoma cells.
    Kim SW, Chao TH, Xiang R, Lo JF, Campbell MJ, Fearns C, Lee JD| | PubMed
  36. Reduction of MTT by aqueous herbal extracts in the absence of cells.
    Shoemaker M, Cohen I, Campbell M| | PubMed
  37. Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro.
    Campbell MJ, Hamilton B, Shoemaker M, Tagliaferri M, Cohen I, Tripathy D| | PubMed
  38. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.
    Campbell MJ, Wollish WS, Lobo M, Esserman LJ| | PubMed
  39. Ductal growth is impeded in mammary glands of C-neu transgenic mice.
    Mukherjee S, Louie SG, Campbell M, Esserman L, Shyamala G| | PubMed
  40. Biological therapies for breast carcinoma: concepts for improvement in survival.
    Borden EC, Esserman L, Linder DJ, Campbell MJ, Fulton AM| | PubMed
  41. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.
    Esserman LJ, Lopez T, Montes R, Bald LN, Fendly BM, Campbell MJ| | PubMed
  42. Clinical trials of idiotype-specific vaccine in B-cell lymphomas.
    Hsu FJ, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R, Levy R| | PubMed
  43. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
    Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R| | PubMed
  44. Tumor resistance induced by syngeneic bone marrow transplantation and enhanced by interleukin 2: a model for the graft versus leukemia reaction.
    Kwak LW, Campbell MJ, Levy R| | PubMed
  45. Interleukin 3 is a growth factor for human follicular B cell lymphoma.
    Clayberger C, Luna-Fineman S, Lee JE, Pillai A, Campbell M, Levy R, Krensky AM| | PubMed
  46. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire.
    Campbell MJ, Zelenetz AD, Levy S, Levy R| | PubMed
  47. Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy.
    Kwak LW, Campbell MJ, Zelenetz AD, Levy R| | PubMed
  48. Ig VH gene expression among human follicular lymphomas.
    Bahler DW, Campbell MJ, Hart S, Miller RA, Levy S, Levy R| | PubMed
  49. Follicular lymphoma: a model of lymphoid tumor progression in man.
    Zelenetz AD, Campbell MJ, Bahler DW, Takahashi S, Oren R, Esserman L, Umetsu DT, Kwak LW, Maloney DG, Brown S| | PubMed
  50. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
    Kwak LW, Campbell M, Levy R| | PubMed
  51. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin.
    Kwak LW, Campbell MJ, Zelenetz AD, Levy R| | PubMed
  52. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
    Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R| | PubMed
  53. Idiotypic variation in a human B lymphoma cell line.
    Berinstein N, Campbell MJ, Lam K, Carswell C, Levy S, Levy R| | PubMed
  54. Functional immunoglobulin light chain genes are replaced by ongoing rearrangements of germline V kappa genes to downstream J kappa segment in a murine B cell line.
    Levy S, Campbell MJ, Levy R| | PubMed
  55. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.
    Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R| | PubMed
  56. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide.
    Campbell MJ, Esserman L, Levy R| | PubMed
  57. Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action.
    Basham TY, Race ER, Campbell MJ, Reid TR, Levy R, Merigan TC| | PubMed
  58. Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants.
    Starnes CO, Carroll WL, Campbell MJ, Houston LL, Apell G, Levy R| | PubMed
  59. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.
    Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy S, Levy R| | PubMed
  60. Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses.
    Lowder JN, Meeker TC, Campbell M, Garcia CF, Gralow J, Miller RA, Warnke R, Levy R| | PubMed
  61. Influence of avidity and idiotope recognition on the modulation of surface immunoglobulin on malignant human B cells by rat monoclonal anti-idiotype antibodies.
    Campbell M, Bieber M, Levy R, Teng NN| | PubMed
  62. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.
    Kaminski MS, Kitamura K, Maloney DG, Campbell MJ, Levy R| | PubMed